Pharmacokinetics and Pharmacodynamics Practice Questions

Q: What type of antagonism is observed between acetylcholine and atropine?

Competitive antagonism. **Explanation:** **1. Why Competitive Antagonism is Correct:** Acetylcholine (ACh) and Atropine compete for the same binding site on the **muscarinic receptors**. In competitive (reversible) antagonism, the antagonist binds to the receptor site, preventing the agonist from binding. This inhibition can be overcome by increasing the concentration of the agonist (ACh), which shifts the dose-response curve to the **right** without changing the maximal response ($E_{max}$). **2. Why Other Options are Incorrect:** * **Physiological Antagonism:** This occurs when two drugs act on **different receptors** to produce opposite physiological effects (e.g., Histamine causing bronchoconstriction via $H_1$ receptors vs. Adrenaline causing bronchodilation via $\beta_2$ receptors). ACh and Atropine act on the *same* receptor. * **Noncompetitive Antagonism:** Here, the antagonist binds to an allosteric site or binds irreversibly to the active site. Increasing the agonist concentration cannot overcome this block, leading to a decrease in the maximal response ($E_{max}$). **3. NEET-PG High-Yield Pearls:** * **Surmountable Blockade:** Competitive antagonism is "surmountable." * **Graph Shift:** Look for a **parallel shift to the right** in the Log Dose-Response (LDR) curve. * **Dissociation Constant ($K_d$):** In competitive antagonism, the $K_d$ (or $EC_{50}$) increases, but the efficacy remains unchanged. * **Clinical Example:** Atropine is the drug of choice for **Organophosphate poisoning** to competitively block the excess ACh at muscarinic sites.

Q: All of the following agents act through nuclear receptors EXCEPT?

Prednisolone. **Explanation:** The question asks for the agent that does **not** act through a nuclear receptor. While all options listed are lipid-soluble hormones or drugs that act on intracellular receptors, there is a specific distinction in their localization. **1. Why Prednisolone is the correct answer:** Glucocorticoids like **Prednisolone** act on the **Glucocorticoid Receptor (GR)**, which is a **Cytoplasmic receptor** (Type I Nuclear Receptor subfamily) [2]. In its inactive state, the GR is bound to Heat Shock Proteins (HSP-90) in the cytoplasm [3]. Upon ligand binding, the receptor dissociates from HSPs, dimerizes, and translocates into the nucleus to modulate gene transcription [2]. Therefore, strictly speaking, its primary location is the cytoplasm, not the nucleus. **2. Why the other options are incorrect:** * **Thyroxine (T4):** Acts on Thyroid Hormone Receptors (TR) which are **constitutively located in the nucleus**, bound to DNA even in the absence of a ligand [4]. * **Rosiglitazone:** This is a Thiazolidinedione (TZD) that acts on **PPAR-gamma** (Peroxisome Proliferator-Activated Receptor gamma), which is a **nuclear receptor** [1]. * **Estrogen:** Acts on Estrogen Receptors (ER). Unlike glucocorticoid receptors, ERs are primarily **located in the nucleus** (Type II) even before the hormone binds. **High-Yield Clinical Pearls for NEET-PG:** * **Cytoplasmic Receptors:** Remember the mnemonic **"VAG"** — **V**itamin D (can be both, but often grouped here), **A**ldosterone (Mineralocorticoids), and **G**lucocorticoids. * **Nuclear Receptors:** Remember **"RET"** — **R**etinoic acid, **E**strogen/Progesterone, and **T**hyroid hormone (T3/T4). * **Mechanism:** All these receptors act as **ligand-activated transcription factors**, leading to a lag period in action (hours to days) and a persistent effect even after the drug is cleared.

Q: What is the value of intrinsic activity for a partial agonist?

Between 0 and +1. ### Explanation **Intrinsic Activity (α)** refers to the ability of a drug to activate a receptor and produce a maximal biological response once it has bound to it. It is measured on a scale from -1 to +1. **Why the Correct Answer is Right:** A **Partial Agonist** binds to a receptor but, even at 100% receptor occupancy, it cannot elicit the maximal response (Emax) that a full agonist would. Therefore, its intrinsic activity is greater than zero (it does produce a response) but less than one (the response is sub-maximal). * **Mathematical Value:** 0 < α < 1. * **Clinical Significance:** In the presence of a full agonist, a partial agonist acts as a **competitive antagonist** because it occupies receptors but produces a weaker effect, effectively "damping" the overall response (e.g., Buprenorphine in opioid use). **Why Other Options are Wrong:** * **Option A (1):** This is the intrinsic activity of a **Full Agonist**, which produces the maximum possible biological response. * **Option B (0):** This is the intrinsic activity of a **Competitive Antagonist**. It has affinity (binds to the receptor) but zero intrinsic activity (produces no response). * **Option D (-1):** This is the intrinsic activity of an **Inverse Agonist**. It binds to the receptor and produces an effect opposite to that of an agonist (decreases constitutive activity). **High-Yield NEET-PG Pearls:** 1. **Affinity vs. Intrinsic Activity:** All agonists and antagonists have affinity, but only agonists (full/partial/inverse) have intrinsic activity. 2. **Pindolol:** A classic example of a partial agonist (Beta-blocker with Intrinsic Sympathomimetic Activity). 3. **Varenicline:** A partial agonist at nicotinic receptors used for smoking cessation. 4. **Aripiprazole:** An atypical antipsychotic that acts as a partial agonist at $D_2$ receptors.

Q: Which of the following H1 receptor antagonists does not have an active metabolite?

Mizolastine. ### Explanation The correct answer is **Mizolastine**. **1. Why Mizolastine is the correct answer:** Mizolastine is a second-generation H1 receptor antagonist [2] characterized by its unique metabolic profile. Unlike many other antihistamines in its class [1], Mizolastine is primarily metabolized in the liver via **glucuronidation** and oxidation into **inactive metabolites**. It does not rely on the formation of an active metabolite to exert its therapeutic effect, which contributes to its predictable pharmacokinetics and lower potential for drug-drug interactions compared to those requiring CYP450 activation. **2. Why the other options are incorrect:** * **Loratadine:** It is a prodrug that is extensively metabolized by CYP3A4 and CYP2D6 into its potent active metabolite, **Desloratadine** [1, 2]. * **Azelastine:** This phthalazinone derivative [2] is metabolized into an active metabolite, **Desmethylazelastine**, which contributes to its long duration of action. * **Ebastine:** It is a prodrug that undergoes near-complete first-pass metabolism by CYP3A4 to form its active metabolite, **Carebastine**. **3. NEET-PG High-Yield Clinical Pearls:** * **Active Metabolite Pairs:** Remember the pairs for exams: Terfenadine → Fexofenadine; Loratadine → Desloratadine; Ebastine → Carebastine; Hydroxyzine → Cetirizine [1, 2]. * **Mizolastine Unique Features:** It has a dual mechanism —it blocks H1 receptors and also inhibits the release of inflammatory mediators (like leukotrienes) from mast cells. * **Safety Note:** Unlike its predecessors (Terfenadine and Astemizole), Mizolastine has a significantly lower risk of causing Torsades de Pointes (QT prolongation), though caution is still advised with potent CYP3A4 inhibitors.

Q: Which of the following drugs does NOT exhibit first-pass metabolism?

Salicylates. ### Explanation **Concept: First-Pass Metabolism** First-pass metabolism (presystemic elimination) is the phenomenon where a drug is metabolized in the gut wall or liver before reaching the systemic circulation. This significantly reduces the bioavailability of orally administered drugs. **Why Salicylates is the Correct Answer:** Salicylates (such as Aspirin) are rapidly absorbed from the stomach and upper small intestine. While they undergo metabolism in the liver, they do **not** undergo significant first-pass metabolism that limits their systemic availability. They have high oral bioavailability (approx. 70–100%). In contrast, the other options are classic examples of drugs with high first-pass extraction. **Analysis of Incorrect Options:** * **Nitroglycerine (B):** This drug has the highest first-pass metabolism (nearly 100%). This is why it is administered sublingually to bypass the liver and reach the coronary arteries immediately. * **Morphine (A):** Morphine undergoes extensive glucuronidation in the liver. Its oral dose is significantly higher than its parenteral dose due to this high first-pass effect. * **Propranolol (C):** A classic example of a drug with high hepatic extraction. Only about 25% of an oral dose reaches the systemic circulation. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for High First-Pass Metabolism:** "**L**ive **N**ightly **P**roperly **M**eta **I**s **S**o **H**ard" (**L**ignocaine, **N**itroglycerine, **P**ropranolol, **M**orphine, **I**mipramine, **S**albutamol, **H**ydrocortisone). * **Routes to bypass first-pass:** Sublingual, Transdermal, and Rectal (partial bypass—lower 1/3rd of the rectum). * **Bioavailability ($F$):** For IV administration, $F = 100\%$. For drugs with high first-pass metabolism, $F$ is significantly low.

Q: Which drug is administered as a racemic mixture of two enantiomers with different pharmacokinetic and pharmacodynamic properties?

Verapamil. **Explanation:** **Verapamil** is a classic example of a drug administered as a **racemic mixture** where the two enantiomers exhibit distinct properties. * **Pharmacodynamics:** The **L-isomer (S-verapamil)** is significantly more potent (10–20 times) as a calcium channel blocker compared to the D-isomer (R-verapamil). * **Pharmacokinetics:** Verapamil undergoes stereoselective first-pass metabolism. The L-isomer is metabolized more rapidly than the D-isomer. This explains why oral doses of verapamil must be much higher than intravenous doses to achieve the same therapeutic effect, as the more active L-isomer is heavily cleared by the liver before reaching systemic circulation. **Analysis of Incorrect Options:** * **A. Dilantin (Phenytoin):** This is an achiral molecule (it does not have a chiral center) and therefore does not exist as enantiomers. It is known for its zero-order kinetics at high therapeutic doses. * **B. Digoxin:** This is a complex steroid glycoside derived from the foxglove plant. While it has multiple chiral centers, it is purified as a single natural stereoisomer, not a racemic mixture. * **D. Octreotide:** This is a synthetic cyclic octapeptide (somatostatin analogue). It consists of specific L- and D-amino acids in a fixed sequence, but it is not administered as a racemic mixture of two mirror-image molecules. **NEET-PG High-Yield Pearls:** * **Other Racemic Mixtures:** Warfarin, Ketamine, and Ibuprofen. * **Single Enantiomers:** Some drugs are developed as single isomers to reduce side effects (e.g., **Levocetirizine** from Cetirizine, **Esomeprazole** from Omeprazole, and **S-Amlodipine**). * **Clinical Note:** The stereoselective metabolism of Verapamil is a frequent exam topic regarding the "First Pass Effect."

Q: An example of covalent drug-receptor interaction is:

Phenoxybenzamine binding to alpha adrenergic receptor. **Explanation:** The correct answer is **D. Phenoxybenzamine binding to alpha adrenergic receptor.** **1. Why it is correct:** Most drug-receptor interactions are reversible and involve weak bonds (ionic, hydrogen, or Van der Waals). However, **Phenoxybenzamine** is a classic example of an **irreversible, non-competitive antagonist**. It undergoes a chemical transformation to form a highly reactive ethyleniminium intermediate, which then forms a **strong covalent bond** with the alpha-adrenergic receptor. Because covalent bonds are stable and difficult to break, the blockade is long-lasting (24–48 hours) and cannot be overcome by increasing the concentration of the agonist. **2. Why the other options are incorrect:** * **A & B (Noradrenaline and Acetylcholine):** These are endogenous neurotransmitters. Physiological signaling requires rapid onset and termination; therefore, they bind via **reversible, non-covalent bonds** to allow for quick dissociation and signal termination. * **C (Prazosin):** Unlike phenoxybenzamine, Prazosin is a **selective, competitive alpha-1 blocker**. It binds reversibly to the receptor, meaning its inhibitory effect can be overcome by increasing the concentration of an agonist (like Noradrenaline). **3. High-Yield Clinical Pearls for NEET-PG:** * **Clinical Use:** Phenoxybenzamine is primarily used in the preoperative management of **Pheochromocytoma** to prevent hypertensive crises. * **The "Epinephrine Reversal" (Dale’s Vasomotor Reversal):** If Epinephrine is given after Phenoxybenzamine, the alpha-mediated vasoconstriction is blocked, leaving the beta-2 mediated vasodilation unopposed, resulting in a **fall** in blood pressure. * **Other Covalent Inhibitors:** Other high-yield examples of covalent/irreversible binding include **Aspirin** (COX enzymes), **Omeprazole** (H+/K+ ATPase), and **Organophosphates** (Acetylcholinesterase).

Q: Sodium and/or potassium ions are involved in the mechanism of action of which of the following receptors?

All of the above. **Explanation:** The correct answer is **All of the above** because all three receptors listed are linked to ion channels (either directly or indirectly) that regulate the flux of sodium ($Na^+$) and/or potassium ($K^+$) ions. 1. **Neuromuscular ($N_m$) and Neuronal ($N_n$) Receptors:** These are **Ionotropic receptors** (Ligand-gated ion channels). When Acetylcholine binds to these nicotinic receptors, it causes the opening of a central pore that is permeable to both $Na^+$ and $K^+$. The rapid influx of $Na^+$ leads to depolarization, which triggers an action potential (muscle contraction in $N_m$ and post-ganglionic firing in $N_n$). 2. **Dopamine Receptors:** These are **Metabotropic receptors** (G-Protein Coupled Receptors - GPCRs). While they don't form a channel themselves, their downstream signaling significantly affects ion conductance. For example, $D_2$ receptors are coupled to $G_i/G_o$ proteins, which often lead to the **opening of $K^+$ channels** (causing hyperpolarization) and the **inhibition of $Na^+$ or $Ca^{2+}$ channels**. **Why "All of the above" is correct:** While the mechanism differs (direct gating for Nicotinic vs. indirect modulation for Dopamine), all three receptors fundamentally rely on the movement of $Na^+$ and/or $K^+$ to exert their physiological effects. **High-Yield Clinical Pearls for NEET-PG:** * **Nicotinic Receptors ($N_m, N_n$):** Always excitatory; work via rapid $Na^+$ influx. * **G-Protein Modulation:** $G_i$ coupled receptors (like $D_2, M_2, \alpha_2$) typically increase $K^+$ efflux, leading to membrane stabilization/hyperpolarization. * **Fast vs. Slow:** Ionotropic receptors (Nicotinic) act in milliseconds, whereas Metabotropic (Dopamine) act in seconds to minutes.

Q: Zero order kinetics means

A constant amount of drug is eliminated per unit time. ### Explanation **Zero-order kinetics** (also known as saturation kinetics or non-linear kinetics) occurs when the elimination rate of a drug is independent of its plasma concentration. **1. Why Option A is Correct:** In zero-order kinetics, the metabolic pathways or transport systems responsible for drug elimination become **saturated**. Because the enzymes are working at their maximum capacity ($V_{max}$), they can only process a **fixed, constant amount** of the drug per unit of time (e.g., 10 mg every hour), regardless of how much drug is present in the blood. **2. Why Other Options are Incorrect:** * **Option B:** This describes **First-order kinetics**, where a constant *fraction* or percentage of the drug is eliminated per unit time. This is the most common pattern for most drugs at therapeutic doses, where the rate of elimination is directly proportional to the plasma concentration. * **Option C:** This is the definition of **Bioavailability ($F$)**, which refers to the proportion of an administered dose that reaches the systemic circulation in an unchanged form. **3. High-Yield Clinical Pearls for NEET-PG:** * **The "WAT" Mnemonic:** Common drugs following zero-order kinetics include **W**arfarin (at high doses), **A**lcohol (Ethanol), **A**spirin (at high doses), and **T**heophylline/Phenytoin. * **Half-life ($t_{1/2}$):** Unlike first-order kinetics, the half-life in zero-order kinetics is **not constant**; it decreases as the plasma concentration decreases. * **Graphing:** On a graph of Plasma Concentration vs. Time, zero-order kinetics produces a **straight line**, whereas first-order kinetics produces a curve. * **Clinical Risk:** Drugs following zero-order kinetics are more prone to toxicity because a small increase in dose can lead to a disproportionately large increase in plasma concentration once saturation occurs.

Question 1

What type of antagonism is observed between acetylcholine and atropine?

Accepted Answer

Competitive antagonism

Answer

Physiological antagonism

Answer

Noncompetitive antagonism

Answer

None of the above

Question 2

All of the following agents act through nuclear receptors EXCEPT?

Accepted Answer

Prednisolone

Answer

Thyroxine

Answer

Rosiglitazone

Answer

Estrogen

Question 3

What is the value of intrinsic activity for a partial agonist?

Accepted Answer

Between 0 and +1

Answer

1

Answer

0

Answer

-1

Question 4

Which of the following H1 receptor antagonists does not have an active metabolite?

Accepted Answer

Mizolastine

Answer

Loratidine

Answer

Azelastine

Answer

Ebastine

Question 5

Which of the following drugs does NOT exhibit first-pass metabolism?

Accepted Answer

Salicylates

Answer

Morphine

Answer

Nitroglycerine

Answer

Propranolol

Question 6

Which drug is administered as a racemic mixture of two enantiomers with different pharmacokinetic and pharmacodynamic properties?

Accepted Answer

Verapamil

Answer

Dilantin

Answer

Digoxin

Answer

Octreotide

Question 7

An example of covalent drug-receptor interaction is:

Accepted Answer

Phenoxybenzamine binding to alpha adrenergic receptor

Answer

Noradrenaline binding to Beta 1 adrenergic receptor

Answer

Acetylcholine binding to muscarinic receptor

Answer

Prazosin binding to alpha 1 adrenergic receptor

Question 8

Esmolol is a short-acting beta-blocker because:

Accepted Answer

Its plasma hydrolysis by esterases is rapid.

Answer

It has more plasma protein binding.

Answer

It has high lipid solubility.

Answer

It has high oral bioavailability.

Question 9

Sodium and/or potassium ions are involved in the mechanism of action of which of the following receptors?

Accepted Answer

All of the above

Answer

Dopamine receptor

Answer

Neuromuscular (Nm) receptor

Answer

Neuronal (Nn) receptor

Question 10

Zero order kinetics means

Accepted Answer

A constant amount of drug is eliminated per unit time

Answer

A constant fraction of the drug in the body is eliminated per unit time

Answer

The fraction of the administered dose that reaches the systemic circulation

Answer

None of the above

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?